Baidu
map

Prostate Cancer P D:原发性肿瘤中p53状态可以预测阿比特龙和恩杂鲁胺在去势难治性前列腺癌中的疗效

2018-01-17 AlexYang MedSci原创

最近,有研究人员测试了是否在原发性肿瘤中,基于组织的p53和PTEN基因组状态能够预测阿比特龙和恩杂鲁胺在去势难治性前列腺癌(CRPC)中的敏感性。研究人员进行了一项回顾性的分析,包括了309名患有CRPC且接受阿比特龙或恩杂鲁胺治疗的连续性病人。在这些病人中,101名男性(33%)具有可以用于分析的原发性肿瘤组织。研究人员利用基因验证免疫组织化学分析筛选了有害的TP53错义突变和PTEN缺失,并

最近,有研究人员测试了是否在原发性肿瘤中,基于组织的p53和PTEN基因组状态能够预测阿比特龙和恩杂鲁胺在去势难治性前列腺癌(CRPC)中的敏感性。研究人员进行了一项回顾性的分析,包括了309名患有CRPC且接受阿比特龙或恩杂鲁胺治疗的连续性病人。在这些病人中,101名男性(33%)具有可以用于分析的原发性肿瘤组织。研究人员利用基因验证免疫组织化学分析筛选了有害的TP53错义突变和PTEN缺失,并且还利用了测序技术。另外,研究人员还比较了病人中有或者没有p53和/或PTEN变异的病人的总生存(OS)和无进展生存(PFS)。

研究发现,48%的病例具有PTNE丢失和27%的病例具有p53核内积累。根据PTEN状态,OS和PFS并没有差异,但是与p53状态具有显著的相关性。具有和不具有p53核内积累的病人中,中值OS分别为16.7个月(95% CI, 14-21.9 月)和31.2个月(95% CI, 24.5-43.4)(HR 2.32; 95% CI 1.19-4.51; P=0.0018)。相似地,具有和不具有p53核内积累的病人中,PFS中值分别为5.5个月(95% CI, 3.2-9.9 个月)和10.9个月(95% CI, 8-15.2个月)(HR 2.14, 95%CI 1.20-3.81; P=0.0008)。在多变量分析中,p53状态与PFS独立相关(HR 2.15; 95% CI 1.03-4.49; P=0.04),并且OS的HR为2.19(95% CI 0.89-5.40; P=0.087)。最后,研究人员指出,p53在原发性肿瘤中的去激活(不是PTEN丧失)在CRPC的新激素疗法中也许能够预测较差的结果。

原始出处:

Benjamin L. Maughan, Liana B. Guedes, Kenneth Boucher et al. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer P D. 4 Jan 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846627, encodeId=b252184662e47, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 20 01:31:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791529, encodeId=b4021e91529b7, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Sep 20 00:31:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364284, encodeId=c7d01364284e0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372392, encodeId=fab213e2392b3, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528442, encodeId=781e152844272, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599786, encodeId=69b21599e86fc, content=<a href='/topic/show?id=c8f93e101f9' target=_blank style='color:#2F92EE;'>#原发性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37101, encryptionId=c8f93e101f9, topicName=原发性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=275018754810, createdName=ssnine, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601963, encodeId=80b716019635f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846627, encodeId=b252184662e47, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 20 01:31:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791529, encodeId=b4021e91529b7, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Sep 20 00:31:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364284, encodeId=c7d01364284e0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372392, encodeId=fab213e2392b3, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528442, encodeId=781e152844272, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599786, encodeId=69b21599e86fc, content=<a href='/topic/show?id=c8f93e101f9' target=_blank style='color:#2F92EE;'>#原发性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37101, encryptionId=c8f93e101f9, topicName=原发性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=275018754810, createdName=ssnine, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601963, encodeId=80b716019635f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846627, encodeId=b252184662e47, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 20 01:31:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791529, encodeId=b4021e91529b7, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Sep 20 00:31:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364284, encodeId=c7d01364284e0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372392, encodeId=fab213e2392b3, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528442, encodeId=781e152844272, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599786, encodeId=69b21599e86fc, content=<a href='/topic/show?id=c8f93e101f9' target=_blank style='color:#2F92EE;'>#原发性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37101, encryptionId=c8f93e101f9, topicName=原发性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=275018754810, createdName=ssnine, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601963, encodeId=80b716019635f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-19 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1846627, encodeId=b252184662e47, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 20 01:31:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791529, encodeId=b4021e91529b7, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Sep 20 00:31:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364284, encodeId=c7d01364284e0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372392, encodeId=fab213e2392b3, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528442, encodeId=781e152844272, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599786, encodeId=69b21599e86fc, content=<a href='/topic/show?id=c8f93e101f9' target=_blank style='color:#2F92EE;'>#原发性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37101, encryptionId=c8f93e101f9, topicName=原发性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=275018754810, createdName=ssnine, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601963, encodeId=80b716019635f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-19 zhishijing
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846627, encodeId=b252184662e47, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 20 01:31:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791529, encodeId=b4021e91529b7, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Sep 20 00:31:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364284, encodeId=c7d01364284e0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372392, encodeId=fab213e2392b3, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528442, encodeId=781e152844272, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599786, encodeId=69b21599e86fc, content=<a href='/topic/show?id=c8f93e101f9' target=_blank style='color:#2F92EE;'>#原发性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37101, encryptionId=c8f93e101f9, topicName=原发性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=275018754810, createdName=ssnine, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601963, encodeId=80b716019635f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-19 freve
  6. [GetPortalCommentsPageByObjectIdResponse(id=1846627, encodeId=b252184662e47, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 20 01:31:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791529, encodeId=b4021e91529b7, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Sep 20 00:31:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364284, encodeId=c7d01364284e0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372392, encodeId=fab213e2392b3, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528442, encodeId=781e152844272, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599786, encodeId=69b21599e86fc, content=<a href='/topic/show?id=c8f93e101f9' target=_blank style='color:#2F92EE;'>#原发性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37101, encryptionId=c8f93e101f9, topicName=原发性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=275018754810, createdName=ssnine, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601963, encodeId=80b716019635f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1846627, encodeId=b252184662e47, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Jun 20 01:31:00 CST 2018, time=2018-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791529, encodeId=b4021e91529b7, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Sep 20 00:31:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364284, encodeId=c7d01364284e0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372392, encodeId=fab213e2392b3, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528442, encodeId=781e152844272, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599786, encodeId=69b21599e86fc, content=<a href='/topic/show?id=c8f93e101f9' target=_blank style='color:#2F92EE;'>#原发性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37101, encryptionId=c8f93e101f9, topicName=原发性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=275018754810, createdName=ssnine, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601963, encodeId=80b716019635f, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Jan 19 12:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=)]
    2018-01-19 sunylz

相关资讯

Curr Cancer Drug Targets:在人类前列腺癌中,SOCS6通过诱导细胞凋亡和抑制血管生成起肿瘤抑制子的作用

之前的研究阐释了细胞因子信号抑制子6(SOCS6)的下调与人类前列腺癌(PCa)恶性发展有关。最近,有研究人员进行了旨在调查SOCS6的肿瘤抑制作用和在PCa中潜在的机制。研究人员利用免疫组化技术比较了在PCa和非癌前列腺组织中SOCS6的表达,并且还评估了SOCS6的表达与各种临床病理特性和病人预后之间的统计学相关性。另外,研究人员还通过在体外(细胞凋亡、千叶和侵入分析)和体内(肿瘤形成、血管生

Clin Chem:循环肿瘤细胞中AR-V7, AR-FL, PSA和KRAS位点点突变的原位检测和定量

液体活检可以在去势难治性前列腺癌(CRPC)中检测雄激素受体剪接变异体7(AR-V7),一种雄激素受体的剪接产物。患有AR-V7阳性循环肿瘤细胞(CTCs)的病人在紫杉烷化疗方面要比新激素治疗效果更好,表明了一种治疗选择性生物标记。同样的,在那些患有胰腺癌(PaCa)的病人中,KRAS变异可以作为预后生物标记。因此,对CTCs的表达和变异情况的调查的技术是迫切需要的。最近,有研究人员报道了将AR-

Brit J Cancer:在前瞻性前列腺癌筛选研究中,具有遗传易感性男性前列腺特异性抗原速度分析

前列腺特异性抗原(PSA)和PSA速度(PSAV)已经被用来鉴定具有前列腺癌风险(PrCa)的男性。IMPACT研究评估了PSA筛选,具体是在由于BRCA1/2的变异而具有PrCa遗传易感性的男性中进行。最近,有研究人员评估了在上述群体中,PSA和PSAV在鉴定PrCa和高等级疾病中的利用。研究人员利用逻辑回归计算了PSAV从而来确定是否PSA或者PSAV能够预测具有提高的PSA值男性的前列腺活检

Lancet Oncol:无症状转移性去势抵抗性前列腺癌:双相雄激素治疗有效

美国约翰·霍普金斯大学医学院Teply等在Lancet Oncol.上发表了一篇关于前列腺癌双相雄激素治疗(BAT)的论文。

BMC Cancer:筛状和导管内前列腺癌与基因组不稳定性的增加和不同的基因组变异有关

侵入性筛状和导管内恶性上皮肿瘤(CR/IDC)与前列腺病人副作用结果有关。最近,有研究人员进行了旨在确定前列腺癌中与CR/IDC相关的分子变异,并且聚焦在基因组不稳定性和体细胞数目改变上(CNA)。研究的数据来源于癌症基因组图谱项目(TCGA,N=260)和加拿大前列腺癌基因组网络(CPC-GENE, N =199)根治性前列腺癌切除术数据库,并用于确定格林森(GS)得分和CR/IDC的情况。研究

Prostate Cancer and P D:生殖细胞中 IL4、MGMT和AKT1变异与前列腺癌特异性死亡率相关

前列腺癌(PCa)是引起死亡的主要因素,并且遗传因素能够影响肿瘤的侵入性。一些生殖细胞变异已经被证明与PCa特异性死亡率(PCSM)相关,但是还需要进一步的重复证据。之前鉴定过的PCSM相关的22个遗传变异在7个群体中进行了基因分型(12082名病人;1544名PCa死亡)。对每一个群体,研究人员利用Cox比例风险模型来计算与每一个变异相关的PCSM风险的风险比和95%置信区间。之后,研究人员利用

Baidu
map
Baidu
map
Baidu
map